Literature DB >> 26894897

Pathogenesis of nonalcoholic steatohepatitis.

Wensheng Liu1, Robert D Baker2, Tavleen Bhatia2, Lixin Zhu2, Susan S Baker3.   

Abstract

Nonalcoholic steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease and a risk factor for cirrhosis and hepatocellular carcinoma. The pathological features of NASH include steatosis, hepatocyte injury, inflammation, and various degrees of fibrosis. Steatosis reflects disordered lipid metabolism. Insulin resistance and excessive fatty acid influx to the liver are two important contributing factors. Steatosis is also likely associated with lipotoxicity and cellular stresses such as oxidative stress and endoplasmic reticulum stress, which result in hepatocyte injury. Inflammation and fibrosis are frequently triggered by various signals such as proinflammatory cytokines and chemokines, released by injuried hepatocytes and activated Kupffer cells. Although much progress has been made, the pathogenesis of NASH is not fully elucidated. The purpose of this review is to discuss the current understanding of NASH pathogenesis, mainly focusing on factors contributing to steatosis, hepatocyte injury, inflammation, and fibrosis.

Entities:  

Keywords:  Apoptosis; Autophagy; Genetic predisposition; Gut microbiota; Hepatic stellate cells

Mesh:

Substances:

Year:  2016        PMID: 26894897     DOI: 10.1007/s00018-016-2161-x

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  234 in total

1.  Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease.

Authors:  Jody Dushay; Patricia C Chui; Gosala S Gopalakrishnan; Marta Varela-Rey; Meghan Crawley; Ffolliott M Fisher; Michael K Badman; Maria L Martinez-Chantar; Eleftheria Maratos-Flier
Journal:  Gastroenterology       Date:  2010-05-05       Impact factor: 22.682

2.  Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis.

Authors:  S J Yang; S Y Hwang; H Y Choi; H J Yoo; J A Seo; S G Kim; N H Kim; S H Baik; D S Choi; K M Choi
Journal:  J Clin Endocrinol Metab       Date:  2011-06-15       Impact factor: 5.958

3.  Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease.

Authors:  Valerio Nobili; Guido Carpino; Anna Alisi; Antonio Franchitto; Gianfranco Alpini; Rita De Vito; Paolo Onori; Domenico Alvaro; Eugenio Gaudio
Journal:  Hepatology       Date:  2012-12       Impact factor: 17.425

Review 4.  Non-alcoholic fatty liver disease: what's new under the microscope?

Authors:  Elizabeth M Brunt
Journal:  Gut       Date:  2011-02-08       Impact factor: 23.059

Review 5.  Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Xue-Qun Zhang; Cheng-Fu Xu; Chao-Hui Yu; Wei-Xing Chen; You-Ming Li
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

6.  Abnormality of autophagic function and cathepsin expression in the liver from patients with non-alcoholic fatty liver disease.

Authors:  Yuka Fukuo; Shunhei Yamashina; Hiroshi Sonoue; Atsushi Arakawa; Eisuke Nakadera; Tomonori Aoyama; Akira Uchiyama; Kazuyoshi Kon; Kenichi Ikejima; Sumio Watanabe
Journal:  Hepatol Res       Date:  2014-02-17       Impact factor: 4.288

Review 7.  Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c.

Authors:  P Ferré; F Foufelle
Journal:  Diabetes Obes Metab       Date:  2010-10       Impact factor: 6.577

Review 8.  Nonalcoholic fatty liver disease: pathology and pathogenesis.

Authors:  Dina G Tiniakos; Miriam B Vos; Elizabeth M Brunt
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

Review 9.  Angiogenesis in liver disease.

Authors:  Mercedes Fernández; David Semela; Jordi Bruix; Isabelle Colle; Massimo Pinzani; Jaume Bosch
Journal:  J Hepatol       Date:  2008-12-31       Impact factor: 25.083

10.  Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease.

Authors:  Yun Shen; Xiaojing Ma; Jian Zhou; Xiaoping Pan; Yaping Hao; Mi Zhou; Zhigang Lu; Meifang Gao; Yuqian Bao; Weiping Jia
Journal:  Cardiovasc Diabetol       Date:  2013-08-28       Impact factor: 9.951

View more
  66 in total

1.  Exercise suppresses NLRP3 inflammasome activation in mice with diet-induced NASH: a plausible role of adropin.

Authors:  Wenqi Yang; Ling Liu; Yuan Wei; Chunlu Fang; Shujing Liu; Fu Zhou; Yaping Li; Ge Zhao; Ziyi Guo; Yuan Luo; Liangming Li
Journal:  Lab Invest       Date:  2020-12-02       Impact factor: 5.662

2.  A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway.

Authors:  Lichen Bao; Jun Yin; Wen Gao; Qun Wang; Wenbing Yao; Xiangdong Gao
Journal:  Br J Pharmacol       Date:  2018-07-03       Impact factor: 8.739

3.  Oxidative stress induced by portal vein embolization in fatty liver: Experimental study of a nonalcoholic steatohepatitis model.

Authors:  Yasutaka Baba; Sadao Hayashi; Kohei Nagasato; Michiyo Higashi; Nanako Tosuji; Shunro Sonoda; Takashi Yoshiura
Journal:  Biomed Rep       Date:  2018-08-08

Review 4.  p62/SQSTM1-Dr. Jekyll and Mr. Hyde that prevents oxidative stress but promotes liver cancer.

Authors:  Koji Taniguchi; Shinichiro Yamachika; Feng He; Michael Karin
Journal:  FEBS Lett       Date:  2016-08-06       Impact factor: 4.124

Review 5.  Extracellular miRNAs: From Biomarkers to Mediators of Physiology and Disease.

Authors:  Marcelo A Mori; Raissa G Ludwig; Ruben Garcia-Martin; Bruna B Brandão; C Ronald Kahn
Journal:  Cell Metab       Date:  2019-08-22       Impact factor: 27.287

6.  Developmental Programming: Impact of Gestational Steroid and Metabolic Milieus on Mediators of Insulin Sensitivity in Prenatal Testosterone-Treated Female Sheep.

Authors:  Muraly Puttabyatappa; Victoria Andriessen; Makeda Mesquitta; Lixia Zeng; Subramaniam Pennathur; Vasantha Padmanabhan
Journal:  Endocrinology       Date:  2017-09-01       Impact factor: 4.736

Review 7.  Molecular and cellular mechanisms of liver fibrosis and its regression.

Authors:  Tatiana Kisseleva; David Brenner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-30       Impact factor: 46.802

8.  Early PQQ supplementation has persistent long-term protective effects on developmental programming of hepatic lipotoxicity and inflammation in obese mice.

Authors:  Karen R Jonscher; Michael S Stewart; Alba Alfonso-Garcia; Brian C DeFelice; Xiaoxin X Wang; Yuhuan Luo; Moshe Levi; Margaret J R Heerwagen; Rachel C Janssen; Becky A de la Houssaye; Ellen Wiitala; Garrett Florey; Raleigh L Jonscher; Eric O Potma; Oliver Fiehn; Jacob E Friedman
Journal:  FASEB J       Date:  2016-12-22       Impact factor: 5.191

9.  Human liver epigenetic alterations in non-alcoholic steatohepatitis are related to insulin action.

Authors:  Vanessa D de Mello; Ashok Matte; Alexander Perfilyev; Ville Männistö; Tina Rönn; Emma Nilsson; Pirjo Käkelä; Charlotte Ling; Jussi Pihlajamäki
Journal:  Epigenetics       Date:  2017-02-23       Impact factor: 4.528

10.  Developmental programming: Changes in mediators of insulin sensitivity in prenatal bisphenol A-treated female sheep.

Authors:  Muraly Puttabyatappa; Jacob D Martin; Victoria Andriessen; Micaela Stevenson; Lixia Zeng; Subramaniam Pennathur; Vasantha Padmanabhan
Journal:  Reprod Toxicol       Date:  2019-03-07       Impact factor: 3.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.